Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hospital Mater DeiBSP:MATD3 +1.45%83 EV-to-EBITDA is 5.61 as of Jul. 14, 2026, which is 35% below its 10-year median of 8.64. GuruFocus rates BSP:MATD3 with a GF Score™ of 83/100 and a GF Value™ of R$5.89 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 505 Healthcare Providers & Services companies, Hospital Mater Dei ranks better than 82.18% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hospital Mater Dei's enterprise value is R$3,216 Mil.
Hospital Mater Dei's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was R$574 Mil. Therefore, Hospital Mater Dei's EV-to-EBITDA for today is 5.61.
The historical rank and industry rank for Hospital Mater Dei's EV-to-EBITDA or its related term are showing as below:
BSP:MATD3'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.28 Med: 8.64 Max: 31.05
Current: 5.61
During the past 9 years, the highest EV-to-EBITDA of Hospital Mater Dei was 31.05. The lowest was -24.28. And the median was 8.64.
BSP:MATD3's EV-to-EBITDA is ranked better than 82.18% of 505
companies
in the Healthcare Providers & Services industry
Industry Median: 11.01
vs BSP:MATD3: 5.61
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Hospital Mater Dei (BSP:MATD3) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hospital Mater Dei's PE Ratio (TTM) for today is calculated as:
Hospital Mater Dei's share price for today is R$4.91.
Hospital Mater Dei's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0.372.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Hospital Mater Dei's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:MATD3 vs HCA, THC, DVA: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Hospital Mater Dei's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hospital Mater Dei EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Hospital Mater Dei's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hospital Mater Dei's EV-to-EBITDA falls into.
Hospital Mater Dei's current Enterprise Value is R$3,216 Mil.
Hospital Mater Dei's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$574 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hospital Mater Dei (BSP:MATD3) has a EV-to-EBITDA of 5.61 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hospital Mater Dei. This is 35% below median its historical median of 8.64. According to the industry distribution chart, Hospital Mater Dei ranks #90 out of 505 companies in the Healthcare Providers & Services industry, placing it in the top 17.8%.
Is Hospital Mater Dei's EV-to-EBITDA too high?
Hospital Mater Dei's current EV-to-EBITDA of 5.61 is 35% below median its 10-year median of 8.64. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.01. Hospital Mater Dei's value of 5.61 is 49% below this industry median. Based on the distribution chart, Hospital Mater Dei ranks #90 out of 505 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Hospital Mater Dei has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hospital Mater Dei's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Hospital Mater Dei ranks #90 out of 505 companies for EV-to-EBITDA. This places Hospital Mater Dei in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 11.01. Hospital Mater Dei's value of 5.61 is 49% below this benchmark. While the company's 10-year median is 8.64 vs. the industry median of 11.01, Hospital Mater Dei has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.01, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hospital Mater Dei's current EV-to-EBITDA of 5.61 is 49% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hospital Mater Dei. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hospital Mater Dei's current EV-to-EBITDA is 5.61, which is 35% below median its own 10-year median of 8.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hospital Mater Dei stock overvalued right now?
Based on GuruFocus' analysis, Hospital Mater Dei (BSP:MATD3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$5.89, compared to a current price of R$4.91 — trading 16.6% below its estimated fair value. The current EV-to-EBITDA is 5.61, which is 35% below median its 10-year median of 8.64 and 49% below the Healthcare Providers & Services industry median of 11.01. Hospital Mater Dei's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Hospital Mater Dei (BSP:MATD3), the current EV-to-EBITDA is 5.61 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hospital Mater Dei (BSP:MATD3) Overvalued in 2026?
Based on GuruFocus' analysis, Hospital Mater Dei stock appears to be undervalued.
The current stock price of R$4.91 is trading 16.6% below its estimated GF Value™ of R$5.89.
GuruFocus considers Hospital Mater Dei to be Modestly Undervalued.
Key valuation signals for BSP:MATD3:
EV-to-EBITDA: 5.61 (35% below median its 10-year median of 8.64)
GF Value™: R$5.89 vs. price of R$4.91 (16.6% below fair value)
Industry Position: 49% below the Healthcare Providers & Services median (#90 of 505)
No single metric tells the full story. See the BSP:MATD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hospital Mater Dei SA is an integrated healthcare ecosystem that provides hospital and oncological services. The company provides a wide range of healthcare services, including hospitalizations, surgeries, oncology treatments, medical appointments, and diagnostic exams.
83GF Score
Get the complete analysis for BSP:MATD3
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:MATD3 has been successfully added to your 
